Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL

NCT07278882 · tracked via the Priya Life Science China tracker

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Phase

Not applicable

Started

2025-12-01

Last updated

2026-04-29

Condition(s) studied

Pediatric Acute Leukemia

Investigational drug(s) / intervention(s)

Health monitoring & reminders for a mobile-phone portal for scheduling a telemedicine clinic visit and receive periodic model-phone messages instructing follow-up blood testing and dose adjustment.

Health monitoring & reminders for a mobile-phone portal for scheduling a telemedicine clinic visit and receive periodic model-phone messages instructing follow-up blood testing and dose adjustment.: Subjects classified as 'Orange Alert' receive mobile-phone alert messages that instruct them to self-adjust dose of oral medication. Subjects classified as 'Red Alert' are directed to a mobile-phone portal for scheduling a telemedicine clinic visit and receive periodic model-phone messages instructing follow-up blood testing and dose adjustment.

Study summary

To assess the efficacy of using mobile technology to improve the percentage of time wherein drug dosing is within the target range

Eligibility

Sex

ALL

Min age

—

Max age

16 Years

Healthy volunteers

Inclusion Criteria: 1. \< 16 years old at diagnosis; 2. having demonstrated ≥ 3 months of \> 90% compliance with using a mobile app to log in records of daily medication and weekly blood test results; 3. no further in-hospital chemotherapy; 4. patient or legal guardian provides informed consent. Exclusion Criteria: None

Primary outcome measure(s)

Percentage of time wherein white blood cell concentration is within the target range — After randomization
Percentage of time wherein white blood cell concentration is within the target range 1.5 - 3.5 × 10\^9/L after randomization.

Trial sites (1)

Facility	City	Region	Status
Institute of Hematology & Blood Diseases Hospital	Tianjin	Tianjin Municipality	Recruiting

More Institute of Hematology & Blood Diseases Hospital, China trials in China

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma Recruiting

Twice-per-weekSelinexor, 2 Days Melphalan Starting soon

A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma. Starting soon

Cohort of Nursing Homes Recruiting

Newly-diagnosed Pediatric Ph-positive B-ALL Protocol Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07278882 on ClinicalTrials.gov ↗ ← All trials in China